DB, MD

Aegerion Pharmaceuticals: Capitalize on Cholesterol

The problem if course is multiple-fold:
1. Just because it lowers cholesterol, does it mean it will lower mortality? The bar for all anti-cholesterol meds will likely be set higher after the ENHANCE trial
2. Just because it' lowers it better than the rest, does it mean it will do well? Crestor languishes in the face of a much older Lipitor?
3. Is it safe? Tough question to answer at this early stage in the game.
4. Will FDA approve it? Will it be fast enough? Will it require more studies?
5. It is a crowded field and it is unclear to me at least, as a physician, that another me-too drug even if slightly more effective will result in a monumental prescription writing shift away from the more established meds.

Thoughts?